Select Page

South Delhi Pharma, New Delhi, India

CYRAMZA (ramucirumab) injection, for intravenous use

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

Facts of Cyramza (ramucirumab)

Product: CYRAMZA (ramucirumab) injection, for intravenous use
Initial U.S. Approval: 2014
Indication: stomach cancer, colorectal cancer, or non-small cell lung cancer
Injection: 100 mg/10 mL (10 mg/mL) or 500 mg/50 mL (10 mg/mL). solution in a single-dose vial
Company: Eli Lilly and Company

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Cyramza (ramucirumab)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Cyramza (ramucirumab) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

6 + 9 =

What Cyramza is ?

CYRAMZA® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:

  • as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
  • in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
  • in combination with docetaxel, for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA.
  • in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
  • as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.

What Ramucirumab is ?

Ramucirumab (trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors.

On 21 April 2014, the US Food and Drug Administration (FDA) approved ramucirumab as a single-agent treatment for advanced gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy.
On 12 December 2014, the FDA approved ramucirumab in combination with docetaxel for treatment of metastatic non-small-cell lung carcinoma (NSCLC) with disease progression during or after first-line platinum-containing chemotherapy.
On 24 April 2015, ramucirumab was approved by FDA for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and fluoropyrimidine.
On 10 May 2019, ramucirumab was approved by FDA as a single agent treatment for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of > 400 ng/mL and have been previously treated with sorafenib.

6 reviews for CYRAMZA (ramucirumab) injection, for intravenous use

  1. Earn Online

    I simply couldn’t go away your website before suggesting that I extremely loved the standard info a person provide for your visitors? Is going to be back ceaselessly to investigate cross-check new posts.

    https://www.blogexpander.com/wondering-how-to-make-money-online-try-these-ideas-today/

  2. Karine Mellott

    F*ckin’ remarkable things here. I am very satisfied to look your post. Thank you a lot and i am having a look ahead to contact you. Will you kindly drop me a e-mail?

    http://www.zovrelioptor.com/

  3. Jetbluemastercard

    Its like you read my mind! You appear to know so much about this, like you wrote the book in it or something. I think that you could do with some pics to drive the message home a little bit, but other than that, this is fantastic blog. An excellent read. I will certainly be back.

    https://votrips.stream/story.php?title=A-very-interesting-site-along-with-great-short-articles!-d6k8j4c1

  4. Skywestonline login

    whoah this blog is fantastic i love reading your articles. Keep up the great work! You know, many people are hunting around for this info, you could help them greatly.

    https://kinsuian.faith/story.php?title=A-quite-appealing-internet-site-with-excellent-posts!-m8a4s1t3

  5. bluebird com activate card

    I am continuously looking online for tips that can aid me. Thanks!

    https://rso.mui.ac.ir/shopping-car-right-here-are-some-ideas-tip-no-7-613

  6. Aolmail.com

    hello there and thank you for your info Ive definitely picked up something new from right here. I did however expertise a few technical issues using this web site, as I experienced to reload the website many times previous to I could get it to load properly. I had been wondering if your web host is OK? Not that I’m complaining, but slow loading instances times will sometimes affect your placement in google and can damage your quality score if advertising and marketing with Adwords. Anyway Im adding this RSS to my email and can look out for much more of your respective intriguing content. Make sure you update this again soon..

    https://bookmarkspot.win/story.php?title=shield-your-internet-experience-including-aol-mail-from-predators#discuss

Add a review

Your email address will not be published.